Oracle Named a Leader in IDC MarketScape: Worldwide Life Sciences R&D

IDC MarketScape leadership highlights Oracle’s scale in real-world data and AI-enabled life sciences research tools.

Rhea-AI Summary

Oracle (ORCL) has been named a Leader in the IDC MarketScape: Worldwide Life Sciences R&D RWD/RWE for Data Platforms, Technology Solutions, and Consulting Services 2026 Vendor Assessment.

The assessment cites Oracle's more than 40 years of delivering real-world data and evidence solutions, including aggregation of EHR data for nearly two decades and an RWD platform launched after the 2022 Cerner acquisition. Oracle also introduced a next-generation AI-powered life sciences platform in 2026 and reports working with every major pharma. Its Life Sciences Data Intelligence integrates customer data with more than 122 million de-identified patient records from over 255 health systems, supported by AI agents for tasks such as cohort identification and regulatory submission support.

Positive

• Named a Leader in IDC MarketScape 2026 life sciences RWD/RWE vendor assessment
• 40+ years delivering real-world data/evidence solutions for life sciences
• 122 million de-identified patient records from over 255 health systems in Oracle Health Real-World Data
• Launched RWD platform after 2022 Cerner acquisition and AI-powered life sciences platform in 2026
• Reported to work with every major pharma across life sciences research
• Platform includes AI agents for cohort identification and regulatory submission support

Negative

• None.

Market Context

ORCL's pre-headline 0.64% gain aligned with PLTR, MSFT, FFIV, and PANW advances of 2.43%, 1.35%, 3.9...

Analysis

ORCL's pre-headline 0.64% gain aligned with PLTR, MSFT, FFIV, and PANW advances of 2.43%, 1.35%, 3.95%, and 2.11%; the recognition arrived within broad peer strength.

Key Figures

RWD/RWE experience: over 40 years Patient records: more than 122 million Health systems: more than 255 +1 more

RWD/RWE experience

over 40 years

Oracle's real-world data and real-world evidence solutions

Patient records

more than 122 million

de-identified records in Oracle Health Real-World Data

Health systems

more than 255

Oracle Learning Health Network

EHR data aggregation

nearly two decades

real-world EHR data through Oracle's health system network

Key Terms

rwd/rwe, synthetic control arm, health economics and outcomes research (heor), pharmacovigilance

4 terms

rwd/rwe medical

"Worldwide Life Sciences R&D RWD/RWE for Data Platforms"

Real-world data (RWD) are health-related information collected outside controlled clinical trials—such as electronic health records, insurance claims, patient registries, and wearables—and real-world evidence (RWE) is the clinical or safety insights generated by analyzing that data. Investors care because RWE can reveal how a drug, device, or treatment performs in everyday medical practice, much like road tests show how a car handles in real traffic versus a lab, and can affect regulatory decisions, market uptake, and revenue forecasts.

synthetic control arm medical

"cohort identification, synthetic control arm generation"

A synthetic control arm is a comparison group for a clinical trial that is created from existing patient data—such as past trials, medical records, or registries—instead of enrolling new patients into a placebo or standard-treatment arm. Investors care because it can shorten timelines, lower development costs, and influence regulators’ confidence in efficacy and safety; think of it as using a carefully matched historical group as a stand-in for recruiting new volunteers.

health economics and outcomes research (heor) medical

"health economics and outcomes research (HEOR)"

Health economics and outcomes research (HEOR) studies how well medical treatments work in the real world and what they cost, combining clinical results, patient experiences, and economic analysis to judge value. For investors, HEOR is like a product report card and price guide: it helps predict whether insurers, hospitals and doctors will adopt and pay for a therapy, influencing sales, pricing power and long-term revenue potential.

pharmacovigilance medical

"clinical research and pharmacovigilance"

Pharmacovigilance is the process of monitoring and assessing the safety of medicines after they are on the market, ensuring that any side effects or risks are identified and managed. For investors, it matters because it helps ensure that pharmaceutical companies maintain safe products, which can influence a company’s reputation, regulatory approval, and financial stability over time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

RWD/RWE for Data Platforms, Technology Solutions, and Consulting Services 2026 Vendor Assessment

AUSTIN, Texas, Sept. 22, 2026 /PRNewswire/ -- Oracle has been named a Leader in the IDC MarketScape: Worldwide Life Sciences R&D RWD/RWE for Data Platforms, Technology Solutions, and Consulting Services 2026 Vendor Assessment.¹ The IDC MarketScape highlights Oracle's "long legacy for providing RWD/RWE solutions to strengthen its customers' regulatory submissions strategy, enhance their market access and reimbursement strategies, and optimize their success for product commercialization." 

The report states, "[Oracle] has delivered RWD/RWE (real-world data/real-world evidence) solutions for over 40 years, aggregating real-world EHR data for nearly two decades through its health system network. It also launched an RWD platform following the 2022 acquisition of Cerner, and a next-generation AI-powered life sciences platform in 2026. Oracle works with every major pharma."

"Oracle's position reflects its long-standing experience working across healthcare and life sciences and its continued investment in AI-enabled capabilities," said Dr. Nimita Limaye, research vice president, Life Sciences R&D Strategy & Technology, IDC. "Oracle brings together real-world data, technology, and scientific and regulatory expertise within an integrated offering that can support organizations across multiple stages of the research lifecycle. With these capabilities, Oracle is uniquely equipped to help life sciences organizations maximize the value and scale of their real-world evidence."

Oracle's Approach to Real-World Data and Evidence
Oracle Life Sciences Data Intelligence integrates customer-supplied data with Oracle Health Real-World Data, which consists of more than 122 million² de-identified, representative patient records generated through Oracle Learning Health Network. The network spans more than 255 health systems, providing a solid foundation for clinical research, regulatory evidence generation, market access, and commercialization initiatives.

The report noted, "It has out-of-the-box and customizable AI agents supporting natural language querying, cohort identification, synthetic control arm generation, health economics and outcomes research (HEOR), safety signal detection, and regulatory submission support."

"Our deep domain expertise, combined with significant investments in AI and real-world data, can help life sciences organizations make more informed decisions," said Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences. "We believe this recognition from IDC MarketScape reflects our experience in real-world evidence and our commitment to helping life sciences organizations turn data into insights that can advance the development of new treatments."

To access the IDC MarketScape for Worldwide Life Sciences R&D RWD/RWE for Data, Platforms, Technology Solutions, and Consulting Services 2026 Vendor Assessment excerpt and to learn more about Oracle Life Sciences solutions, visit: https://www.oracle.com/life-sciences/real-world-data-real-world-evidence-idc-report/.

The Oracle Health and Life Sciences Summit will take place September 22–24, 2026, in Orlando, Florida. For more information, visit: https://www.oracle.com/health/health-life-sciences-summit/.

About IDC MarketScape
IDC MarketScape vendor assessment model is designed to provide an overview of the competitive fitness of technology and service suppliers in a given market. The research methodology utilizes a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each vendor's position within a given market. IDC MarketScape provides a clear framework in which the product and service offerings, capabilities and strategies, and current and future market success factors of IT and telecommunications vendors can be meaningfully compared. The framework also provides technology buyers with a 360-degree assessment of the strengths and weaknesses of current and prospective vendors.

About Oracle Life Sciences
Oracle Life Sciences is a leader in cloud technology, pharmaceutical research, and consulting, trusted globally by professionals in both large and emerging companies engaged in clinical research and pharmacovigilance, throughout the therapeutic development lifecycle, including pre- and post-drug launch activities. With more than 20 years of experience, Oracle Life Sciences is committed to supporting clinical development and leveraging real-world evidence to deliver innovation and accelerate advancements—empowering the life sciences industry to improve patient outcomes. Learn more at www.oracle.com/lifesciences.

About Oracle
Oracle offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud. For more information about Oracle (NYSE: ORCL), please visit us at www.oracle.com.

Trademarks
Oracle, Java, MySQL and NetSuite are registered trademarks of Oracle Corporation. NetSuite was the first cloud company—ushering in the new era of cloud computing.

¹ IDC MarketScape: Worldwide Life Science R&D RWD/RWE for Data Platforms, Technology Solutions, and Consulting Services 2026 Vendor Assessment (Doc #US54122226, August 2026)
²All data pulled from Oracle Health Data Intelligence and current as of May 2026 and calculated using distinct person IDs, which leverage a multipoint match algorithm to account for and remove duplicates within a single health system; patients who have visited multiple health systems may appear more than once in the data.

View original content to download multimedia:https://www.prnewswire.com/news-releases/oracle-named-a-leader-in-idc-marketscape-worldwide-life-sciences-rd-302883751.html

SOURCE Oracle

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What scope of real-world data does Oracle Health Real-World Data include?

Oracle Health Real-World Data consists of more than 122 million de-identified, representative patient records generated through the Oracle Learning Health Network. This network spans more than 255 health systems and is positioned as a foundation for clinical research, regulatory evidence generation, market access, and commercialization initiatives.

What AI-enabled capabilities does Oracle Life Sciences Data Intelligence offer?

The IDC MarketScape notes that Oracle provides out-of-the-box and customizable AI agents that support natural language querying, cohort identification, synthetic control arm generation, health economics and outcomes research (HEOR), safety signal detection, and regulatory submission support.

How can stakeholders access the IDC MarketScape excerpt about Oracle?

An excerpt of the IDC MarketScape: Worldwide Life Sciences R&D RWD/RWE for Data Platforms, Technology Solutions, and Consulting Services 2026 Vendor Assessment and more information about Oracle Life Sciences solutions are available at https://www.oracle.com/life-sciences/real-world-data-real-world-evidence-idc-report/.

When and where is the Oracle Health and Life Sciences Summit taking place?

The Oracle Health and Life Sciences Summit is scheduled for September 22–24, 2026, in Orlando, Florida. Additional details are provided at https://www.oracle.com/health/health-life-sciences-summit/.